The combination of histone deacetylase inhibitor HBI8000 and EZH2 inhibitor SHR2554 exhibited dramatic antitumor activity in diffuse large B‐cell lymphoma (DLBCL).21 This evidence concerns the gene EZH2 and diffuse large B-cell lymphoma.